Guggenheim Remains Bullish on Eli Lilly (LLY) Ahead of Q1 2026 Results

On March 30, 2026, Guggenheim updated its exemplary up of the first-quarter information and lowered the firm’s terms people for Eli Lilly and Company (NYSE:LLY) from $1,168 to $1,163, portion keeping a “Buy” rating. The update came successful anticipation of the company’s Q1 2026 results.

This update coincides with ongoing expert attraction toward Eli Lilly and Company (NYSE:LLY)’s positioning successful the rapidly expanding oral obesity market.

RBC Capital reaffirmed its “Outperform” standing and $1,250 terms people for the banal connected March 16, 2026. The steadfast highlighted that the updated 44-week Phase 2 ACCESS II information for Structure Therapeutics’ aleniglipron look akin to Eli Lilly and Company (NYSE:LLY)’s Phase 2 information for orforglipron, with nary visibly superior profile.

According to the concern firm, the information lend to the competitory statement astir oral obesity therapies and whitethorn bespeak the emergence of a caller rival for marketplace share.

However, Eli Lilly and Company (NYSE:LLY)’s ain catalyst remains the firm’s superior focus, with orforglipron’s April 10, 2026, PDUFA day and imaginable motorboat expected to beryllium the much important operator of the stock.

Eli Lilly and Company (NYSE:LLY) is simply a healthcare institution that specializes successful quality pharmaceutical products and offers cardiometabolic wellness & oncology products.

While we admit the imaginable of LLY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.